ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2026
Cardiovascular Outcomes and Safety of GLP-1 Receptor Agonists in Elderly Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes. However, evidence specific to elderly patients remains limited. Elderly patients with diabetes are associated with high cardiovascular (CV) risk and increased susceptibility to adverse events. Therefore, this study systematically evaluated the CV outcomes and safety of GLP-1 RAs in elderly patients with T2DM. Methods: PubMed, Embase and Web of Science were searched for randomized controlled trials (RCTs) published up to January 2024 that compared GLP-1 RAs with placebo or other controls in patients aged ≥65 years, with cardiovascular outcomes as the primary endpoint. Safety outcomes, including gastrointestinal adverse events and hypoglycemia, were also analyzed. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using a random-effects model. Results: The review was registered with PROSPERO (CRD42024582164). Of 2,425 screened articles, five full-text publications (reporting six independent RCTs) involving 8,889 patients were included. The mean age was 71.8 years. Compared with placebo, GLP-1 RAs significantly reduced MACE by 21% (RR 0.79, 95% CI 0.70-0.90; Conclusion: These findings suggest that GLP-1 RAs confer significant cardioprotective benefits in elderly patients with T2DM, although gastrointestinal adverse effects warrant careful monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.